Article Menu

Export Article

More by Authors Links

Article Data

  • Views 2478
  • Dowloads 146

Original Research

Open Access

Childhood malignant ovarian germ cell tumors: a single institution experience

  • C. Yang1,3
  • J. Tan2
  • C.C. Li1,3
  • J. Zhang1,3
  • X.R. Kong1,3
  • Z. Zhao1,3
  • X. Deng1,3
  • L. Peng1,3
  • S. Wang1,3,*,

1Ministry of Education Key Laboratory of Child Development and Disorders, the Children's Hospital of Chongqing Medical University, Chongqing, China

2Clinical Department of Children's Hospital of Chongqing Medical University, lijia Campus, Chongqing, China

3Department of Pediatric Surgical Oncology, Children's Hospital of Chongqing Medical University, Chongqing, China

DOI: 10.12892/ejgo3661.2017 Vol.38,Issue 5,October 2017 pp.700-703

Published: 10 October 2017

*Corresponding Author(s): S. Wang E-mail: wangshan778@163.com

PDF (131.67 kB) View Full-text

Abstract

Purpose of investigation: This study aimed to analyze the clinical characteristics and outcome of children with malignant ovarian germ cell tumors (MOGCTs), and to investigate the therapeutic strategy. Materials and Methods: All patients with MOGCTs in a single institution during the period January 2001 to December 2012 were analyzed according to the characteristics of patients, treatment, and outcome. Results: Eight-nine patients with MOGCTs had a median age 9.5 (range, 0-15) years. Abdominal pain and abdominal distension were the most frequent clinical presentations. Elevated AFP was observed in 78 cases (87.6%). Eighty-seven patients received surgery plus chemotherapy. The surgical procedures consisted of salpingo-oophorectomy plus omentectomy (n=39), salpingo-oophorectomy (n=39), and oophorectomy (n=11). Five patients died: three from disease, one from leukopenic sepsis, and one from disseminated varicella. The overall five-year survival rate was 95.5% for all patients, 100% for Stage I, 96.2% for Stage II, 95% for Stage III, 91.7% for Stage IV, and 71.4% for relapse patients, respectively. Forty-one out of 49 patients in puberty or reproductive age had regular menstrual cycles. Six patients had menostaxis, and two patients required psychological input during the follow up period. Two patients delivered healthy infants without congenital defects. Conclusion: The prognosis of malignant ovarian germ cell tumor is favorable. Surgery combined with platinum-based chemotherapy can improve curative efficacy and survival. Further investigation of novel and high-dose chemotherapic regimens is needed for the patients with relapsed tumors. Sex hormone replacement therapy is not necessary for most patients receiving fertility-preserving surgery.

Keywords

Pediatrics; Malignant ovarian germ cell tumor (MOGCT); Chemotherapy; Survival rate.


Cite and Share

C. Yang, J. Tan, C.c. Li, J. Zhang, X.r. Kong, Z. Zhao, X. Deng, L. Peng, S. Wang. Childhood malignant ovarian germ cell tumors: a single institution experience. European Journal of Gynaecological Oncology. 2017; 38(5): 700-703. doi: 10.12892/ejgo3661.2017

URL:

https://www.ejgo.net/articles/10.12892/ejgo3661.2017

References

[1] Skinner M.A., Schlatter M.G., Heifetz S.A., Grosfeld J.L.: “Ovarian neoplasms in children”. Arch. Surg., 1993, 128, 849.

[2] Biswajit D., Patil C.N., Sagar T.G.: “Clinical presentation and outcome of pediatric ovarian germ cell tumor: a study of 40 patients”. J. Pediatr. Hematol. Oncol., 2010, 32, e54.

[3] Sah S.P., Uprety D., Rani S.: “Germ cell tumors of the ovary: a clinicopathologic study of 121 cases from Nepal”. J. Obstet. Gynaecol. Res., 2004, 30, 303.

[4] Gershenson D.M.: “Management of ovarian germ cell tumors”. J. Clin. Oncol., 2007, 25, 2938.

[5] von A.D.: “Malignant lesions of the ovary in childhood”. Semin. Pediatr. Surg., 2005, 14, 100.

[6] Norris H.J., Zirkin H.J., Benson W.L.: “Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases”. Cancer, 1976, 37, 2359.

[7] Cicin I., Eralp Y., Saip P., Ayan I., Kebudi R., Iyibozkurt C., et al.: “Malignant ovarian germ cell tumors: a single-institution experience”. Am. J. Clin. Oncol., 2009, 32, 191.

[8] Biswajit D., Patil C.N., Sagar T.G.: “Clinical presentation and outcome of pediatric ovarian germ cell tumor: a study of 40 patients”. J. Pediatr. Hematol. Oncol., 2010, 32, e54.

[9] Bao P.P., Zheng Y., Wu C.X., Peng P., Gong Y.M., Huang Z.Z., et al.: “Population-based survival for childhood cancer patients diagnosed during 2002-2005 in Shanghai, China”. Pediatr. Blood Cancer, 2012, 59, 657.

[10] Araz N.C., Guler E.: “Delays in diagnosis of childhood cancer in southeastern Turkey and the associated factors”. Pediatr. Hematol. Oncol., 2015, 32, 153.

[11] Chukwu B.F., Ezenwosu O.U., Ikefuna A.N., Emodi I.J.: “Diagnostic delay in pediatric cancer in Enugu, Nigeria: a prospective study”. Pediatr. Hematol. Oncol., 2015, 32, 164.

[12] Panteli C., Curry J., Kiely E., Pierro A., de Coppi P., Anderson J., et al.: “Ovarian germ cell tumours: a 17-year study in a single unit”. Eur. J. Pediatr. Surg., 2009, 19, 96.

[13] Lass A.: “The fertility potential of women with a single ovary”. Hum. Reprod. Update, 1999, 5, 546.

[14] De Backer A., Madern G.C., Oosterhuis J.W., Hakvoort-Cammel F.G., Hazebroek F.W.: “Ovarian germ cell tumors in children: a clinical study of 66 patients”. Pediatr. Blood Cancer, 2006, 46, 459.

[15] Cass D.L., Hawkins E., Brandt M.L., Chintagumpala M., Bloss R.S., Milewicz A.L., et al.: “Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15- year period”. J. Pediatr. Surg., 2001, 36, 693.

[16] Billmire D., Vinocur C., Rescorla F., Cushing B., London W., Schlatter M., et al.: “Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study”. J. Pediatr. Surg., 2004, 39, 424.

[17] Terenziani M., Massimino M., Casanova M., Cefalo G., Ferrari A., Luksch R., et al.: “Childhood malignant ovarian germ cell tumors: a monoinstitutional experience”. Gynecol. Oncol., 2001, 81, 436.

Submission Turnaround Time

Top